Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, Rosym
Search This Board:
Last Post: 4/26/2015 12:37:37 AM - Followers: 718 - Board type: Free - Posts Today: 1



Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
 For further information, please visit www.Amarantus.comor connect with the company in FacebookTwitter, LinkedIn & Google+

 

 

 
PRESS RELEASES & NEWS ARTICLES

 

Risk / Reward Favorable With Amarantus Bio, But Management Must Execute In 2015
By Jason Napodano, CFA  -  Friday, April 10, 2015

Developing clinical-stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL April 9, 2015
April 9, 2015
Amarantus Reports 2014 Financial Results and Business Overview - 
 First pharmaceutical customer in the first quarter of 2015, garnered its first pharmaceutical customer in the first quarter of 2015, as the interest in trials of experimental Alzheimer's therapies is beginning to increase with high-profile successes renewing hope for the field.
April 7, 2015
Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
March 26, 2015
Amarantus Shareholder Update: Fundamental Progress on the Pipeline and Strategy Continues
Thursday, March 26th, 2015 

A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason NapodanoWednesday, March 4, 2015
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Feb. 18, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia - The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
Amarantus Creates Alzheimer`s Disease Diagnostics Scientific Advisory Board
 FEBRUARY 3RD, 2015
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015



Predicting Alzheimer's before it starts
Published on Apr. 8, 2015
 

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014
 

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014
 

Amarantus BioScience
Oct. 19, 2014

 

 

 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com


Gerald's email address

Gerald@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

info@vstocktransfer.com

www.VStockTransfer.com 


 
 
  Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

 
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen  cool
 
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
 



 

                                    Developing cinical-stage products in neurology, psychiatry and orghan indications
             BUSINESS UPDATE CONFERENCE CALL  April 9, 2015
        
                        
     
  •              
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 04/09/2015 05:26:36 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 04/09/2015 03:30:16 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 04/08/2015 02:01:18 PM
AMBS News: Current Report Filing (8-k) 04/07/2015 09:11:50 AM
AMBS News: Amarantus Reports 2014 Financial Results and Business Overview 04/07/2015 06:00:00 AM
PostSubject
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#112872   This can take a month or two to jjr04001 04/26/15 12:37:37 AM
#112871   A positive opinion for human mesencephalic astrocyte-derived neurotrophic dshade 04/24/15 12:18:47 PM
#112870   Committee for Orphan Medicinal Products (COMP) Disney714 04/24/15 12:11:08 PM
#112869   and Dominion is long on AMBS. Holding and dshade 04/24/15 09:26:27 AM
#112868   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 04/24/15 09:16:09 AM
#112867   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 04/24/15 09:15:53 AM
#112866   150,000,000 Share DILUTION Coming Sgt. Pepper 04/24/15 09:15:41 AM
#112865   Company just fine. Brn injry, Alzhmrs, Prknsns, all dshade 04/24/15 09:04:51 AM
#112864   This company hasn't done anything worthy of a Deputy123 04/24/15 08:06:35 AM
#112863   AMBS! Raddude_rude 04/23/15 04:08:24 PM
#112862   yo yo trading dshade 04/23/15 01:42:36 PM
#112861   $AMBS$ Must be nice...I couldn't pick anything up under .04! JJAAMMAANN 04/23/15 10:51:54 AM
#112860   Hence why some of us bought down there dshade 04/23/15 09:21:48 AM
#112859   Lol this dropped to .035? wow, even with TradeSmart 04/23/15 04:12:18 AM
#112857   been here since .007 so I see where dshade 04/22/15 04:18:52 PM
#112856   Are you serious? Where is the strength? Deputy123 04/22/15 04:17:44 PM
#112855   scares short when it nears .05 on strength dshade 04/22/15 03:00:19 PM
#112854   nope...they are just awaitin the finall approval for Alapis 04/22/15 11:52:33 AM
#112853   I believe it was posted with link a dshade 04/22/15 11:50:38 AM
#112852   what indication? Alapis 04/22/15 11:38:46 AM
#112851   Tomorrow they report another new Orphan drug app? dshade 04/22/15 11:37:28 AM
#112849   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 04/22/15 09:11:20 AM
#112848   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 04/22/15 09:11:05 AM
#112847  Restored 150,000,000 Share DILUTION Coming Sgt. Pepper 04/22/15 09:10:46 AM
#112845   Thanks for sharing JPetroInc 04/21/15 09:19:48 PM
#112844   Still sideways. :-( TekNerd 04/21/15 04:39:03 PM
#112843   Everyday it's the same post toxic this toxic gulf shores man 04/21/15 09:47:02 AM
#112842   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 04/21/15 09:17:54 AM
#112841   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 04/21/15 09:17:23 AM
#112840   150,000,000 Share DILUTION Coming Sgt. Pepper 04/21/15 09:17:03 AM
#112839   Thank you. jjr04001 04/20/15 10:40:20 PM
#112838   Daily TA Chart JPetroInc 04/20/15 09:24:46 PM
#112837   Weekly chart looks bullish. jjr04001 04/20/15 08:05:57 PM
#112836   That would be another nice addition dshade 04/20/15 01:47:01 PM
#112835   MANF ODD news on deck soon JPetroInc 04/20/15 12:23:16 PM
#112834   as everyone knows, Dominion actually believes in AMBS dshade 04/20/15 09:54:41 AM
#112833   I can't read those posts. Dominion holds it's shares dshade 04/20/15 09:54:10 AM
#112832   Everyday it's the same post toxic this toxic gulf shores man 04/20/15 09:49:18 AM
#112831   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 04/20/15 09:38:22 AM
#112830   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 04/20/15 09:38:07 AM
#112829   150,000,000 Share DILUTION Coming Sgt. Pepper 04/20/15 09:37:55 AM
#112828   imageshack.com/a/img537/7394/VddqXe.png JPetroInc 04/20/15 07:00:04 AM
#112827   The Man ?@nomorefor 7h7 hours ago Rosym 04/20/15 06:59:42 AM
#112826   Thanks jeffshir, sounds good! Rosym 04/19/15 10:18:40 PM
#112825   New optimistic tweet from GC jeffshir 04/19/15 09:59:48 PM
#112824   Either we have a decision or one will Aviator84 04/18/15 04:42:25 AM
#112823   Hallelujah - GREEN JPetroInc 04/17/15 05:12:33 PM
#112822   Good weekend to all. dshade 04/17/15 03:52:09 PM
#112821   No chart? JPetroInc 04/17/15 10:47:17 AM
#112820   I think we soon break the middle bb jjr04001 04/17/15 10:26:32 AM
PostSubject